WHY DON’T WE HAVE CURES FOR COMPLEX
DISEASEs LIKE PARKINSON’S?
Firstly, we do not know all that we could know. There are millions of pages of research unread
and uncorrelated — far too much data for people to handle.
Secondly, drug discovery has been driven by a one-size-fits-all model that fails to reflect the complex interactions that take place inside
the human brain.
We set our focus on Parkinson’s disease, which affects about 10 million people worldwide. In addition to the toll in human suffering, Parkinson’s costs the U.S. economy alone $25 billion a year. It is one of the most difficult problems of systems biology, one that will not be solved by a single target approach but requires understanding and fixing of the diseased brain as a whole. This complexity makes it the ideal target
for artificial intelligence (AI).
In order to produce results, we have overcome major technological obstacles in AI. We regularly publish our solutions in the highest
ranking publication outlets and conferences, such as ACL and NIPS, while also developing intellectual property.